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A rapid and reproducible high-resolution capillary zone electrophoresis (CZE) method capable of resolv-
ing the charge isoforms of intact heparan-N-sulfatase (HNS) has been developed to monitor the charge
consistency across different batches of HNS. Separation was carried out using a bare fused silica capillary
with a buffer system composed of 25mM Tris, pH 8.0. This CZE method allowed the separation and inte-
gration of 14 peaks, each arising from differences in the amount of sialic-acid andmannose-6-phosphate
bearing glycoforms,whichwere conﬁrmedusing enzymaticallymodiﬁed samples. Standard conditioningapillary zone electrophoresis
soform
eparan-N-sulfatase
lycosylation
eterogeneity
and rinsing conditions of the capillary were used to achieve optimal repeatability. Excellent day-to-day
precision was obtained for migration times of each peak relative to the electroosmotic ﬂow marker with
relative standard deviation (RSD)≤0.5%. The precision of the relative peak areas (peak area percentages)
ranged from 0.6% to 2.8% RSD for the major isoforms (peaks 3–12), from 4.0% to 5.0% RSD for peaks 1 and
2, and from 7.4% to 23.2% RSD for peaks 13 and 14. Themethod was able to discriminate charge variation
across different batches of HNS, including those with both signiﬁcant and minor process changes.. Introduction
Heparan-N-sulfatase (HNS) is a lysosomal enzyme involved in
he degradation of heparan sulfate. A deﬁciency in HNS causes the
enetic disordermucopolysaccharidosis type IIIA or Sanﬁlippo syn-
rome type A, a rare autosomal recessive disease occurring in 1 of
00,000 live births [1]. The disease is manifested by severe neuro-
ogical disorder and, at present, no treatment options are available.
he potential for enzyme replacement therapy, however, is
Abbreviations: BGE, background electrolyte buffer; CZE, capillary
one electrophoresis; EOF, electroosmotic ﬂow; HNS, heparan-N-sulfatase;
PAE-PAD, high-performance anion-exchange pulsed amperometric detec-
ion; M6P, mannose-6-phosphate; RSD, relative standard deviation;
ris–HCl, Tris(hydroxymethyl)aminomethane hydrochloride; Tris–base,
ris(hydroxymethyl)aminomethane; Gly–Gly, diglycine; HEPES, 4-(2-
ydroxyethyl)piperazine-1-ethanesulfonic acid; NP40, Tergitol-type NP40 nonyl
henoxypolyethoxylethanol; EDTA, ethylenediaminetetraacetic acid; CIEF, cap-
llary isoelectric focusing; CITP, capillary isotachophoresis; SDS, sodium dodecyl
ulphate; NP40, tergitol-type NP-40 nonyl phenoxypolyethoxylethanol.
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currently being evaluated [2]. Produced frommammalian cells, the
recombinant enzyme is a54.7 kDaglycoprotein containing5poten-
tial N-glycosylation sites with a diversity of structures that include
those having charged sialic acid and mannose-6-phosphate (M6P)
saccharides. Some of these structures, such as those bearing termi-
nalM6P, areknowntobe important forbio-efﬁcacy; other sitesmay
have roles in protein stability and/or solubility [3–5]. Importantly,
the diversity of different glycoforms present in the ﬁnal product
can be inﬂuenced by both upstream cell culture and downstream
puriﬁcation processes.
The production of recombinant protein therapeutics in a
commercial setting requires careful control of the manufacturing
processes, which in turn, necessitates a battery of sensitive analyti-
cal methodologies to both elucidate the physiochemical properties
and to monitor the purity and stability of the products. The ability
to detect subtle physiochemical differences between puriﬁed
batches is therefore critical in achieving a controlled process,
as well as a consistent, safe, and efﬁcacious product. Variations
between batches are always a trigger point for questions from
regulatory agencies.
The molecular charge of a protein is a particularly impor-
tant attribute. Most recombinant therapeutic glycoproteins have a
degree of chargemicro-heterogeneity that can arise frommodiﬁca-
Open access under CC BY license.tions in protein structure, such as deamidation, and/or differences
in the carbohydrate moieties linked to the polypeptide chain. The
degree of charge imparted by the carbohydrate structures has been
shown to have a signiﬁcant impact on the bio-efﬁcacy and serum
.
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alf-life of a glycoprotein, as well as its antigenicity, solubility, and
rotease resistance [6–8]. Therefore, the quantitative analysis and
haracterizationof thenative-chargeheterogeneityof recombinant
roteins is an important component of product development.
A number of different analytical techniques for monitoring
ative-charge heterogeneity have been successfully employed for
oth characterization and lot release in the biopharmaceutical
ndustry. These include ion exchange chromatography, gel elec-
rophoresis isoelectric focusing [9], capillary isoelectric focusing
CIEF) [10], imaged capillary isoelectric focusing [11], and capil-
ary zone electrophoresis (CZE)[11–14]. Although each of these
echniques offers strengths and weaknesses, the best method for
esolving charge heterogeneity of a given protein is determined on
case-by-case basis.
Following a minimalist approach, CZE, the simplest of these
echniques, often provides the fastest and most precise separa-
ions. The separation is performed under homogeneous conditions
nd the same buffer is used in the capillary and reservoirs. In
ZE, unlike conditions found in CIEF or capillary isotachophoresis
CITP), individual isoforms separate because of differences in their
lectrophoretic mobilities. This is a function of both the protein’s
harge and its hydrodynamic radius under speciﬁc conditions. In
his study, a simple and reproducible CZE method was developed
o detect and quantify the different charged isoforms of intact HNS.
ost importantly, this CZE method can accurately discriminate
ubtle variations in the native-charge peak groups ofHNSproduced
n various batches.
. Materials and methods
.1. Chemicals and reagents
Sodium hydroxide solutions (1.0N and 0.1N) and ultra pure
ater were provided by Agilent Technologies (Wilmington,
E, USA). Tris(hydroxymethyl)aminomethane hydrochloride
Tris–HCl), Tris(hydroxymethyl)aminomethane (Tris–base),
iglycine (Gly–Gly), and 4-(2-hydroxyethyl)piperazine-1-
thanesulfonic acid (HEPES) buffers, tergitol-type NP-40 nonyl
henoxypolyethoxylethanol (NP40), and sodium dodecyl sulphate
SDS) were supplied by Sigma–Aldrich (St. Louis, MO, USA). The
ackground electrolyte buffer (BGE) was prepared by making
5mM stock solutions of both Tris–HCl and Tris–base. The pH of
ris–HCl was adjusted to pH 8 using the Tris base solution. The
esulting buffer was ﬁltered through a 0.22m nylon or Teﬂon
lter and stored in a plastic bottle. Alkaline phosphatase and
euraminidase were purchased from Roche Diagnostics (Indi-
napolis, IN, USA). N-glycosidase F was obtained from Prozyme
San Leandro, CA, USA)
.2. HNS preparation
HumanHNSwasproduced inaHT1080humanﬁbrosarcomacell
ine by Shire. Puriﬁed HNS batches were obtained by a combina-
ion of various chromatographic steps. The protein was formulated
n 5mM sodium phosphate, 145mM sodium chloride, pH 7.0, at a
oncentration of 15mg/mL. Sampleswere diluted to a ﬁnal concen-
ration of 1mg/mL in 0.1× BGE. The protein buffer was sufﬁciently
iluted to prevent bandbroadening via antistacking. Samples were
ot ﬁltered.
.3. CZE conditionsCapillary zone electrophoresis was performed on an Agilent
100 instrument equipped with a photo-diode array detector and
hemStation software from Agilent Technologies (Wilmington,
E, USA). Bare fused silica capillary columns (104 cm×50m id,ical and Biomedical Analysis 85 (2013) 67–73
total length=112.5 cm) were also supplied by Agilent Technolo-
gies. Prior to ﬁrst use, the capillary was rinsed for 1h with 1.0N
sodium hydroxide, 5min with water, and then 10min with BGE
(25mM Tris, pH 8.0). The capillary was stored overnight in BGE
to provide optimal migration time precision. Samples were intro-
duced into the anodic end of the capillary by pressure injection
for 2 s at 50mbar. The voltage was +30kV, which generated a cur-
rent of approximately 8A. The capillary temperature was 30 ◦C.
The detection wave length was 200nm with a band pass of 8nm.
A reference wavelength was not used. Data were collected with a
peak width at <0.006min (0.062 s response time)(40Hz). A neg-
ative peak on each electropherogram marked the electroosmotic
ﬂow (EOF) breakthrough, which represented the elution time for
the neutral marker. This was conﬁrmed using mesityl oxide. (Data
not shown).
Between injections, the capillary was rinsedwithwater for 30 s,
0.1N sodiumhydroxide for 3min, water for 30 s, and BGE for 6min.
For isoform population studies, the relative area for each peak was
calculated by dividing itsmigration time corrected peak area by the
sum of the corrected areas for all 14 peaks. For precision studies,
uncorrected peak areas were employed. Reportable values con-
sisted of an average of 3 injections. New buffer preparations were
made for 5 of the 7 assays. A total of 4 different capillaries were
used.
2.4. N-glycan mapping by anion-exchange chromatography
TheHNSsamplewasdenaturedat100 ◦C for3–4min in thepres-
ence of 0.5% SDS, followed by enzymatic release of glycans with
N-glycosidase F.Heparan-N-sulfatase sampleswere incubatedwith
N-glycosidase F (30mU/3L) for 4–6h at 37 ◦Cwith 0.9%NP40, fol-
lowed by a second addition of N-glycosidase F, and an additional
17–19h incubation at 37 ◦C. Separation of the released glycans was
performed by high-performance anion-exchange pulsed amper-
ometric detection (HPAE-PAD), using a CarboPac PA-1 analytical
column equipped with a CarboPac PA-1 guard column (Dionex,
Sunnyvale, CA, USA). Glycans were applied to the column in
12mM sodium acetate/100mM sodium hydroxide, followed by
elution with a 12–300mM sodium acetate gradient (6.4mM/min)
in 100mM sodium hydroxide for 45min. Using a ﬂow rate of
1mL/min and the column at ambient room temperature, glycans
eluted in the order of increasing negative charge.
2.5. Glyco-digest
Heparan-N-sulfatase samples were treated by adding 40L of
sample (600g)with 10L of 10×phosphorylationbuffer in oneof
the following ways: (1) 10L alkaline phosphatase, (2) 10L neu-
raminidase, (3) 10L alkaline phosphatase +10L neuraminidase,
or (4) no treatment. Samples were brought to 100L total volume
by addition of MilliQ water and allowed to incubate for 4h at 37 ◦C.
3. Results and discussion
3.1. Method development
Initial CZE evaluation of HNS charge heterogeneity involved
investigating different buffer types and conditions. The parameters
of 5 buffer types were evaluated for improved resolution. For all
studies under discussion, a 50m column was used. Table 1 sum-
marizes the ﬁndings of the impact of pH, buffer type, and buffer
conditions on the HNS isoform separation. Tris was best for both
separation and detection. Although 25mM HEPES (pH 7.9) and
Gly–Gly (pH 8) worked well for separation, detection was worse
due to UV absorption at 200nm by each buffer. Borate buffer (15
or 25mM, pH 8.1) was inferior. Addition of sodium chloride, urea,
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Table 1
Assessment of different CZE conditions.
Buffer type Results
Tris Resolved 14+ peaks
Borate (15mM, 25mM, pH 8.0) Both concentrations evaluated: 15mM gave the best resolution Resolution not as good as Tris
HEPES (25mM, pH 8.0) Comparable resolution to Tris
Gly–Gly (25mM, pH 8.0) Resolved peaks, but resolution inferior to Tris
Buffer conditions Results
Concentration (20–100mM Tris, pH 8.0) 20–30mM worked well, higher concentrations resulted in loss of peak resolution
pH (25mM Tris, pH 7.0–8.5) Best resolution seen with pH 8.0
25mM Tris, pH 8.0 +25mM NaCl Addition of NaCl signiﬁcantly reduced peak resolution
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all uncharged glycans, and peak groups 2, 3, and 5 consisted of
mono-, di-, and tri-sialylated glycans, respectively. The carbohy-
drate structures present in peak groups 4 and 7 were glycans with
mono- and di-M6P groups, respectively. Peak group 6 consisted of
Fig. 1. CZE proﬁle of HNS lot C. Separation allowed for the (a) identiﬁcation and (b)
integration of 14 isoforms in expanded view. The negative peak (*) represents the25mM Tris, pH 8.0, buffer age Aged buffer r
ZE, capillary zone electrophoresis; Gly–Gly, diglycine; HEPES, 4-(2-hydroxyethyl)p
ydroxyethylcellulose, or ethylenediaminetetra acetic acid (EDTA)
o 25mM Tris worsened the separation. In addition, the age of
he prepared buffer was found to have a negative impact on peak
esolution. Buffer stock solutionswere found to be stable. Peak res-
lution deteriorated when the experimental conditions deviated
rom the optimum in either direction, both for buffer pH and buffer
oncentration. Optimal separation conditions were pH 8.0 with
5mMTris buffer. Themost reproducible results were foundwhen
he capillary was allowed to equilibrate with fresh buffer, other-
ise a gradual decrease in migration times was noted. Although
his decrease would stabilize within a day, the capillary was best
tored overnight with buffer.
It is oftenbest tousea short capillaryandoptimize thebuffer and
uffer additives. ForHNS, it provedbetter tousea longer capillary to
ptimize separation. This was effective only because of the low dif-
usion coefﬁcient of the protein and the apparent lack of interaction
etween the protein and the capillary wall. The longest length of
apillary that would ﬁt in the instrument’s cassette was employed
104 cm). Although the run time increased from about 6min with
72 cm capillary to 16min with a 104 cm capillary, the resolution
as improved with the longer capillary despite the reduced ﬁeld
trength. Both runs were at +30kV. Even with these best efforts,
aseline resolution of the glycoforms could not be obtained (Fig. 1),
et results were still analytically useful.
.2. Investigation of peak identities
.2.1. Optimized conditions
Using theoptimized conditions, thenative-chargeproﬁleofHNS
ot C showed at least 14 distinct peaks. The presence of a strong
OFprovidedmigration of positive andnegative charged ions in the
amedirection. The order of elutionwas positively charged species,
ollowed by neutral species, and negatively charged species. No
ositive ions were observed. Longermigration times corresponded
ith species of increased negative charge, since these solutesmore
trongly countermigrate toward the anode. Fig. 1a shows the CZE
roﬁle for HNS lot C in this study and Fig. 1b shows the integration
f the 14 isoforms in lot C in expanded view.
.2.2. CZE analysis for glycosylation
In order to determine if the basis for this charge heterogene-
ty was due to glycosylation, CZE was performed on samples
retreated with the enzymes neuraminidase and/or phosphatase,
hich release sialic acid and phosphate, respectively. Fig. 2a shows
he glycol-characterization of HNS charge heterogeneity usingHNS
ot C samples pretreated with phosphatase, neuraminidase, or
oth. Treatment with a combination of both enzymes signiﬁcantly
educed the complexity of the electropherogram, with a predom-
nant peak and several minor peaks all shifting closer toward the
OF marker, which was expected due to the removal of negatived peak resolution
zine-1-ethanesulfonic acid; Tris, Tris(hydroxymethyl)aminomethane.
charge. The presence of additional minor peaks was likely due to
incomplete removal of either sialic acid and/or phosphate residues.
3.2.3. Glycan mapping
To link the presence of the additional minor peaks to incom-
plete removal of the charged carbohydrate species, total N-glycan
analysis was performed on the same samples to determine if these
residues still remained on the glycans. Using HPAE-PAD glycan
mapping, released glycans eluted in the order of increasing charge
characteristics and were classiﬁed into 7 distinct peak groups.
Fig. 2b shows the HPAE-PAD results. Peak group 1 consisted ofEOFmarker. Conditions: bare fused silica capillary, 104 cm length×50mid;buffer,
25mM Tris at pH 8.0; voltage, +30kV; temperature, 30 ◦C; injection, 100mbar;
detection, 200nm.
CZE, capillary zone electrophoresis; EOF, electroosmotic ﬂow; HNS, heparan-N-
sulfatase; Tris, Tris(hydroxymethyl)aminomethane.
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Fig. 2. Glyco-characterization of HNS charge heterogeneity. Samples of HNS lot
C were pretreated with either phosphatase (green), neuraminidase (red), both
phosphatase and neuraminidase (pink), or no treatment (blue-control), and then
analyzed by (a) CZE, and (b) total N-glycan analysis (HPAE-PAD) after treatment
with N-glycosidase F. The electropherograms in (a) represent intact proteins while
the chromatograms in (b) represent free N-glycans without protein.
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Fig. 3. Run-to-run repeatability of the method. Electropherograms of HNS lot C for
run-to-run repeatability study. Figure represents 3 injections of a single sample.
are shown in a side-by-side comparison and demonstrate that the
method is robust within 20% of target buffer concentration.
Table 2
Day-to-day precision of relative peak areas, migration times, and relative migration
times for 7 independent assays over 16 weeks.
Peak area (%) Migration time Relative
migration time
Isoform Mean RSD (%) Mean RSD (%) Mean RSD (%)
Iso-1 1.2 5.0 12.9 0.8 1.15 0.3
Iso-2 2.9 4.0 13.1 0.8 1.16 0.3
Iso-3 7.1 1.1 13.2 0.9 1.18 0.4
Iso-4 8.9 1.1 13.4 0.9 1.19 0.4
Iso-5 12.0 1.2 13.5 0.9 1.21 0.4
Iso-6 13.2 1.0 13.7 0.9 1.22 0.4
Iso-7 13.6 0.9 13.9 0.9 1.24 0.4
Iso-8 12.3 0.6 14.1 0.9 1.25 0.4
Iso-9 10.5 0.9 14.2 0.9 1.27 0.4
Iso-10 8.0 1.1 14.4 0.9 1.28 0.4
Iso-11 5.5 1.4 14.6 0.9 1.30 0.4
Iso-12 3.1 2.8 14.8 1.0 1.31 0.4
Iso-13 1.3 7.4 14.9 1.0 1.33 0.5
Iso-14 0.4 23.2 15.1 0.9 1.35 0.3ZE, capillary zone electrophoresis; HNS, heparan-N-sulfatase; HPAE-PAD, high-
erformance anion-exchange pulsed amperometric detection; N, neuraminidase;
, phosphatase.
ybrid glycans containing both sialic acid and M6P. These results
how that even after digestion with both neuraminidase and phos-
hatase, small amounts of the mono-sialylated and mono-M6P
eaks remained attached to the protein. This was likely due to
he fact that some of these structures remained inaccessible to
leavage, and was consistent with the lack of a single homogenous
lycoproteinpeakwhenanalyzedbyCZE.Overall, results conﬁrmed
hat the basis for the native charge heterogeneity seen by CZE was
ue to differences in both sialic acid and M6P content.
.3. Method precision and robustness
Measurements of method precision included run-to-run and
ay-to-dayprecision forbothmigration timeandpeakarea. Inaddi-
ion, the robustness of the method was evaluated for the critical
arameters of pH and buffer concentration.
.3.1. Run-to-run precision
HNS lot C was used to evaluate the day-to-day precision of the
elative peak areas and migration times of the 14 peaks indicated
n Fig. 1. Triplicate injections were performed 7 times over a 16-
eek period. The relative standard deviation (RSD) exceeded 5%
nly for peak groups 1, 13, and 14, which was expected due to
heir low abundance (<2%). Fig. 3 shows the overlaid electrophero-
rams,which represent 3 injections of a single sample. The absolute
igration time precision was always 1% or better for the average
f 3 injections. When corrected for the EOF, the precision further
mproved to 0.3–0.5% RSD..3.2. Day-to-day precision
The day-to-day precision of the relative peak areas (peak area
ercentages) is shown in Table 2. Seven independent assays wereConditions as per Fig. 1.
HNS, heparan-N-sulfatase.
performed over a 3- to 4-month period. Relative peak area RSDs
ranged from 0.6% to 2.8% for isoforms 3–12, 4.0% to 5.0% for iso-
forms 1 and 2, and 7.4% to 23.2% for isoforms 13 and 14. As with
day-to-day precision, the higher RSDs for isoforms 1–2 and 13–14
were expected due to their low relative areas. The large negative
peak preceding the isoforms (neutral marker) was used as the ref-
erencemarker (tEOF) for calculating relativemigration time. Table 2
compares the day-to-day precision formigration time (tm) and rel-
ative migration time (tm/tEOF). Day-to-day precision was obtained
for both migration time and relative migration times with RSDs
≤1.0% and 0.5%, respectively. The neutral marker migration time
was approximately 11.2min, and within any given assay, the RSD
for migration times was typically <0.5%.
3.3.3. Buffer and pH robustness
Robustness of the currentmethodwas assessed using HNS lot D
for variations in both pH and buffer composition. The CZE proﬁles
at pH7.89, 8.00, and8.11 are shown in a side-by-side comparison in
Fig. 4a. These results demonstrate that themethod is robust within
this range of pH. In Fig. 4b, CZE proﬁles at 20, 25, and 30mM TrisRSD, relative standard deviation.
RSDswere calculated from n=7 analysis. Each analysiswas performed on a different
dayoveraperiodof4months.Most analysesused freshbufferpreparationsandwere
performed on 3 different capillaries.
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Fig. 4. CZE pH and buffer robustness. CZE electropherograms of HNS lot D run
using (a) 25mM Tris at pH 8.11 (blue), pH 8.00 (red), and pH 7.89 (green) and (b)
20mM (blue), 25mM (red), and 30mM (green) Tris at pH 8.00. Other conditions
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Fig. 5. CZE proﬁles of different HNS lots. Overlaid electropherograms of HNS lot C
(blue) with (a) HNS lot E and (b) HNS lot F. HNS lot F has additional peak groups
labeled x and y. Conditions are identical to those in Fig. 1.re given in Fig. 1.
ZE, capillary zone electrophoresis; HNS, heparan-N-sulfatase; Tris,
ris(hydroxymethyl)aminomethane.
.4. Charge heterogeneity of different HNS lots
.4.1. Quantitative charge differences
This method can discriminate quantitative charge differences
etweenHNS lots producedbydifferent processes. In order to elim-
nate bias due to solute velocity, migration time corrected peak
reas were employed when calculating the relative percentage of
ach glycoform. While this correction did not result in huge differ-
nces compared with uncorrected areas due to the narrow range
f migration times, it was still important to perform the correc-
ion to ensure accuracy. Fig. 5a shows the CZE proﬁle of HNS lot E,
able 3
omparison of relative peak areas (%) of isoforms for different HNS lots.
Run 1 Run 2
Isoform Lot C Lot E Lot C Lot F
Iso-x ND ND ND 0.6
Iso-y ND ND ND 1.6
Iso-1 1.4 1.5 1.3 5.4
Iso-2 3.3 3.9 3.1 5.7
Iso-3 7.4 8.5 7.4 10.7
Iso-4 9.3 10.7 9.3 9.1
Iso-5 12 12.1 12.3 12.8
Iso-6 13.4 12.2 13.4 11.4
Iso-7 13.3 11.7 13.5 10.9
Iso-8 12.1 10.3 12.2 9.1
Iso-9 10.3 9 10.3 7.5
Iso-10 7.8 7.4 7.6 5.8
Iso-11 5.2 5.6 5.2 4.3
Iso-12 3 3.8 2.9 2.9
Iso-13 1.3 2.1 1.2 1.5
Iso-14 0.3 1.1 0.3 0.7
D, not determined.CZE, capillary zone electrophoresis; HNS, heparan-N-sulfatase.
which was produced using the same downstream process as HNS
lot C. Although the same peaks groups are present in both lots C
and E, subtle differences in the peak distributions or “ﬁngerprints”
are apparent. Fig. 5b shows the CZE proﬁle of HNS lot F, which
was produced using a different process than lot C. The downstream
processing of lot F involved a deviation in the buffer composition,
which resulted in a skewed elution proﬁle and a ﬁnal drug sub-
stance having an additional population of isoforms. Comparedwith
lot C, lot F has additional peaks (Fig. 5b, x and y) indicative of less
acidic isoforms. The potential value of this CZE proﬁling method is
that it could help identify upstream processes that contribute to
these differences in charge. The quantitative results for the rela-
tive peak areas of lots E and F, compared with lot C, are listed in
Table 3. Fig. 6a and b provide graphical comparisons that plot the
percentage of total area vs isoformnumber for lots C, E, and F. Com-
bined, these results demonstrate that this optimized CZE method
is capable of distinguishing the subtle charge differences observed
between similar lots due to typical variations within a process,
as well as the more substantial changes seen in lots produced by
different processes.
3.4.2. Large-scale variability from the same process
Four large-scale HNS lots (H, I, J, and K) were produced to
demonstrate the robustness of a clinical phase manufacturing pro-
cess. The charge proﬁles of the lots were evaluated by CZE; results
in Fig. 7 demonstrate that HNS lots J and K show an increase in
less negative species compared with HNS lots H and I. Importantly,
something had changed in the upstream/downstream process that
impacted the isoform distributions. Thus, this CZE method can be
used to discern subtle changes in HNS isoform distribution pro-
duced by the same process.
72 D.S. Roseman, R. Weinberger / Journal of Pharmaceutical and Biomedical Analysis 85 (2013) 67–73
Fig. 6. Peak group plots of different HNS lots. Relative area vs peak group plots
comparing HNS lot C (blue) to (a) lot E (red) and (b) lot F (black). In (a) peaks are
from the same downstream process, whereas (b) used a different process.
HNS, heparan-N-sulfatase.
Fig. 7. Relative peak area plots of 4 large-scale HNS lots. (a) Relative area vs peak
group plots comparing 4 large-scale process representative lots and (b) overlaid
electropherograms of lot H (blue) with lot K (red). Conditions are identical to those
in Fig. 1.
HNS, heparan-N-sulfatase.
Fig. 8. Glyco-characterization of HNS charge heterogeneity by CZE. Electropherograms of HNS lots L (blue) and M (red) in the (a) absence or (b–d) presence of the glycol-
digesting enzymes alkaline phosphatase and/or neuraminidase.
CZE, capillary zone electrophoresis; HNS, heparan-N-sulfatase.
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.4.3. CZE glycodigest analysis
CZE was used to assess the native charge heterogeneity of 2
linical scale HNS lots, L and M, each produced by a different man-
facturing process. The native charge proﬁle of HNS lot L wasmore
egative, compared with lot M (Fig. 8a). In order to determine if
lycosylation was the basis for this charge heterogeneity, CZE was
erformed on samples pretreated with neuraminidase and phos-
hatase. Treatment with these enzymes signiﬁcantly reduced the
omplexity of the electropherogram and the resulting CZE proﬁles
ere then indistinguishable, providing evidence that the charge
ifferences found between the 2 lots were a result of higher sialic
cid and/or M6P content in lot L (Fig. 8b). The presence of addi-
ional minor peaks was due to incomplete removal of either sialic
cid and/or phosphate residues, conﬁrmed previously by N-glycan
roﬁling. To see if the charge differences were due to differences
n sialic acid or M6P, CZE was performed on samples pretreated
ith either neuraminidase or alkaline phosphatase (Fig. 8c and d).
esults demonstrated that the basis for the more negative charge
een in HNS lot L was due to increased amounts of both sialic acid
nd M6P.
. Conclusions
Capillary zone electrophoresis, an accepted and established
echnique, was used in a novel way to demonstrate slight varia-
ions in charge between batches of HNSmade by the same process.
his CZE-based method was developed to quantitatively measure
he charge heterogeneity of intact HNS and to help monitor pro-
ess consistency in the development of a highly robust puriﬁcation
rocess. The research presented here establishes that the following
onditions are optimal for the detection of the various isoforms of
ecombinant HNS produced by HT1080 human ﬁbrosarcoma cell
ines: 104 cm length×50m id bare fused silica capillary; 25mM
ris, pH 8.0 buffer; +30kV voltage; 30 ◦C temperature; 2 s, 50mbar
ressure injection; with a detection wavelength of 200nm. This
ZE method is reproducible, precise, and robust. Fourteen peaks,
ach differing in charge and attributed to the absence or presence
f varying amounts of sialic acid and M6P groups, were resolved in
arious HNS batches. The method is capable of discriminating sub-
le differences in charge across HNS batches and can be used as a
est of product quality and consistency for HNS drug development
nd production.
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